Pasar al contenido principal
U.S. flag

Un sitio oficial del Gobierno de Estados Unidos

Así es como usted puede verificarlo

Dot gov
Los sitios web oficiales usan .gov
Un sitio web .gov pertenece a una organización oficial del Gobierno de Estados Unidos.
Https

Los sitios web seguros .gov usan HTTPS
Un candado ( Candado Un candado cerrado ) o https:// significa que usted se conectó de forma segura a un sitio web .gov. Comparta información sensible sólo en sitios web oficiales y seguros.

  • Quiénes somos
    • Sobre la DEA
    • Mission
    • Nuestra historia
    • Divisiones Nacionales
      • Atlanta
        • Atlanta Leadership
        • Atlanta Contacts
      • Caribbean
        • Caribbean Leadership
        • Caribbean Contacts
      • Chicago
        • Chicago Leadership
        • Chicago Contacts
      • Dallas
        • Dallas Leadership
        • Dallas Contacts
      • Detroit
        • Detroit Leadership
        • Detroit Contacts
      • El Paso
        • El Paso Leadership
        • El Paso Contacts
      • Headquarters
      • Houston
        • Houston Leadership
        • Houston Contacts
      • Los Angeles
        • Los Angeles Leadership
        • Los Angeles Contacts
      • Louisville
        • Louisville Leadership
        • Louisville Contacts
      • Miami
        • Miami Leadership
        • Miami Contacts
      • New England
        • New England Leadership
        • New England Contacts
      • New Jersey
        • New Jersey Contacts
      • New Orleans
        • New Orleans Leadership
        • New Orleans Contacts
      • New York
        • New York Leadership
        • New York Contacts
      • Omaha
        • Omaha Leadership
        • Omaha Contacts
      • Philadelphia
        • Philadelphia Leadership
        • Philadelphia Contacts
      • Phoenix
        • Phoenix Leadership
        • Phoenix Contacts
      • Rocky Mountain
        • Rocky Mountain Contacts
      • San Diego
        • San Diego Leadership
        • San Diego Contacts
      • San Francisco
        • San Francisco Contacts
      • Seattle
        • Seattle Contacts
      • St. Louis
        • St. Louis Leadership
        • St. Louis Contacts
      • Washington, DC
        • Washington Leadership
        • Washington Contacts
    • DEA Museum
    • Oficinas extranjeras
      • Africa
      • Andean
      • Caribbean
      • Europe
      • Far East
      • Middle East
      • North and Central America
      • Southern Cone
    • Divisiones operativas
      • División de Aviación
      • División de Control de Desvíos
    • Wall of Honor
    • Contáctenos
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • Lo que hacemos
    • Orden público
      • DEA Office of Training
        • Office of Training Programs
      • El Paso Intelligence Center (EPIC)
        • Leadership
        • Mission
        • Services
        • Contacts
      • Forensic Sciences
        • Computer Forensics Program
        • Environmental Management
        • Laboratories
      • Intelligence
      • Operations
        • Administrative Law Judges
        • DEA Asset Forfeiture
        • Domestic Cannabis Suppression / Eradication Program
        • HIDTA
        • OCDETF
        • State and Local Task Forces
    • Educación y prevención
      • DEA’s Family Summit
      • Operation Engage
      • Community Outreach
      • Red Ribbon
        • Kiki and the History of Red Ribbon Week
        • Red Ribbon Toolkit - Resources For Your Community
      • Just Think Twice
      • Campus Drug Prevention
      • Get Smart About Drugs
      • Operation Prevention
    • Información sobre las drogas
      • Drug Policy
      • Drug Scheduling
      • The Controlled Substances Act
    • News
      • Alerts
      • Press Releases
      • Most Wanted Fugitives
        • All Fugitives
      • Stories
      • Events
      • Speeches
      • Testimony
    • Campaigns
      • One Pill Can Kill
        • Partner Toolbox
        • Social Media Campaign
      • DEA National Prescription Drug Take Back Day
  • Carreras
    • Agentes especiales
      • Preguntas frecuentes de los agentes especiales
      • Anuncios de empleo para agentes especiales
    • Investigador de desvíos
      • Diversion Investigator Job Announcement
    • Especialista en investigación de inteligencia
      • Anuncios de trabajo de especialista en investigación de inteligencia
      • Preguntas frecuentes de los especialistas en investigación de inteligencia
      • Autoridad de contratación de la Categoría A: Especialista en investigación de inteligencia
    • Carreras de ciencias forenses
    • Carreras profesionales y administrativas
    • Carreras para estudiantes y de nivel básico
    • Cómo aplicar
      • Empleador con igualdad de oportunidades
      • Requisitos de empleo
      • Cómo reclamar la preferencia de los veteranos
      • Consideración prioritaria
      • Beneficios
      • Veteranos y personas con discapacidades
  • Recursos
    • Recovery Resources
    • Data and Statistics
      • Domestic Arrests
      • Staffing and Budget
    • Ley de Libertad de Información
      • About FOIA
      • Contact DEA FOIA
      • Make a Request
      • What Happens After Making a Request
      • Requester Categories
      • Fees Charged
      • Fee Waiver
      • FOIA FAQ
      • FOIA Logs and Reports
      • FOIA Library
      • Additional FOIA Links
      • FOIA Exemptions
      • What Are Exclusions?
      • Privacy Act
      • Privacy Act Exemptions
      • Privacy Impact Assessment and Management Information Systems
    • Publications
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
      • Victim Witness Assistance Program Resources

United States Drug Enforcement Administration

  • Buscar
  • Menú Completo

Main Menu

  • Quiénes somos
  • Lo que hacemos
  • Carreras
  • Recursos
  • Recibir Actualizaciones
  • Scam Alert
  • English
  • ES

PUBLIC SAFETY ALERT

DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine - DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine

Drug Enforcement Administration

Shelly S. Howe Special Agent in Charge
San Diego
@DEASanDiegoDiv
Enero 20, 2022
Contact: Kelly McKay
Phone Number: (571) 324-6204
For Immediate Release

San Diego Pharmacy Pays $105,000 Penalty for Illegitimately Dispensing Opioids

SAN DIEGO – San Diego’s Balboa Pharmacy has paid $105,000 to resolve allegations that it illegally dispensed opioids and other dangerous drugs to its patients, according to a settlement agreement signed by Balboa Pharmacy and the United States. The settlement stems from the United States’ continued efforts to combat the opioid epidemic on all fronts, including this investigation of whether Balboa Pharmacy illegally dispensed opioids to its patients in violation of the federal Controlled Substances Act.

The Controlled Substances Act states that pharmacists have a responsibility to only fill prescriptions that are written for a legitimate medical purpose while acting in the usual course of professional practice. The United States alleged that Balboa Pharmacy failed to meet its responsibility when it filled opioid prescriptions without resolving—or often even attempting to resolve - “red flags” that the prescriptions raised. “Red flags” are indications that a prescription may be invalid. According to the settlement agreement, Balboa Pharmacy filled prescriptions without resolving the following commonly known red flags:

  • large quantities of opioids well above guidelines for treating patients, which sometimes exceeded a daily Morphine Milligram Equivalent of 100;
  • dangerous combinations of drugs, including duplicative therapy; opioids and benzodiazepines (e.g., Valium, Xanax); and opioids, benzodiazepines, and muscle relaxants (e.g., Soma), a combination that is colloquially referred to by drug abusers as the “trinity” because of the rapid euphoric effects of this combination of drugs;
  • patients who received prescriptions from multiple prescribers, which sometimes were for the same types of controlled substances or for dangerous combinations of drugs; and
  • filling prescriptions for patients early, which includes filling a patient’s prescription before the patient’s earlier prescription for the same drug ran out.

The investigation exemplifies the Department of Justice’s willingness to investigate pharmacies that may be filling dangerous prescriptions without first confirming the legitimacy of each prescription. Public health experts have long warned health care providers that overdose risk is elevated in patients receiving medically prescribed opioids, particularly those receiving high dosages. Pharmacists should carefully track the potency of opioids dispensed to patients by noting the Morphine Milligram Equivalent (MME, also commonly referred to as Morphine Equivalent Dose or MED) of prescribed opioids. Among other things, tracking MMEs advances better practices for pain management by reinforcing the need to consider alternatives to using high-dosage opioids to treat pain, and to appropriately justify decisions to use opioids at dosages that place patients at high risk of addiction, abuse, and overdose. Furthermore, dispensing high dosages increases the risk that patients will divert opioids.

“This investigation is a reminder that all pharmacies have a responsibility to ensure that prescriptions are issued for a legitimate medical purpose,” said Special Agent in Charge Shelly S. Howe. “Failure to do so allows prescriptions to become subject to abuse and diversion, fueling the ongoing opioid epidemic. DEA will continue to hold pharmacies, such as Balboa Pharmacy, accountable.”

“Pharmacies are the last line of defense protecting the public from addictive opioids and other controlled substances,” said U.S. Attorney Randy S. Grossman. “This office will pursue pharmacists who carelessly disregard red flags, opting instead to rubberstamp questionable prescriptions. We will continue to use all available tools to combat the serious opioid epidemic.”

In addition to the settlement agreement, the DEA and Balboa Pharmacy entered into a Memorandum of Agreement in October 2021 in which Balboa Pharmacy agreed to, among other things, develop policies and procedures and training that address the identification and resolution of “red flags.”

To report a tip directly to a DEA representative regarding medical personnel writing suspicious opioid prescriptions and pharmacies dispensing large amounts of opioids, call (571) 324-6499, or visit the DEA’s website (https://www.deadiversion.usdoj.gov/) and click on “Report Illicit Pharmaceutical Activities.”

The claims resolved by this settlement are allegations only and there has been no determination of liability.

AGENCIES: United States Attorney’s Office

###

 

  • Facebook
  • Twitter
  • Email

SAMHSA Behavioral Health Treatment Locator

  • Quienes Somos
    • Sobre
    • Divisiones Nacionales
    • Oficinas Extranjeras
    • Contáctenos
    • Museo DEA
  • Lo Que Hacemos
    • Prevención de Drogas
    • Aplicacion de la Ley
    • División de Control de Desvío
    • Noticias
  • Carreras
    • Resumen
    • Agente Especial
    • Investigador de Desvío
    • Especialista en Investigación de Inteligencia
  • Recursos
    • Información sobre las Drogas
    • Programa de Asistencia al Empleado
    • Empleador con Igualdad de Oportunidades
    • Ley de Libertad de Información (FOIA)
    • Publicaciones
    • Galerías Multimedia
    • Programa de Asistencia a Testigos para Víctimas
  • Hacer Negocios
    con la DEA
    • Resumen
    • Proveedores Actuales
    • Futuros Vendedores
    • Cláusulas de Seguridad
    • Formularios de Seguridad
    • Programa de Pequeñas Empresas
  • Políticas
    • Accesibilidad, Complementos y Política
    • Políticas Legales y Descargos de Responsabilidad
    • Antidiscriminación y Represalias Acto
    • Política de Privacidad
    • Política de Igualdad de Oportunidades en el Empleo del U.S. DOJ
    • USA.gov
    • Protección de Denunciantes
Inicio

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook Twitter LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster